 |
Dr
Peter C Butler, M.D.
Professor of Medicine
Center Director
(310) 206-7312
pbutler@mednet.ucla.edu
|
Dr. Peter Butler's research
is focused on abnormal insulin secretion in diabetes, the causes
of beta cell death in diabetes and the possibility to foster islet
regeneration in humans with diabetes. After obtaining his MD at
the University of Birmingham, UK in 1980, Dr Peter Butler under
went training in internal medicine in Edinburgh and Newcastle upon
Tyne in the UK. He then underwent training in Endocrinology at the
University of Newcastle upon Tyne and then at the Mayo Clinic in
Rochester MN where he was also a research fellow. He was then appointed
to a clinical faculty position at Mayo Clinic in Endocrinology,
Diabetes and Metabolism. He was also the Associate Director of the
General Clinical Research Center and led an NIH funded research
program. After six years on the faculty at the Mayo Clinic he was
appointed to the Chair of Diabetes at the University of Edinburgh
in Scotland where he established the first Clinical Research Center
in the UK. He returned to the USA in 1999 when he was appointed
to Chief of Endocrinology, Diabetes and Hypertension at the University
of Southern California moving to the University of California, Los
Angeles in 2002. At UCLA he has established the Larry Hillblom Islet
Research Center, a free standing building that houses investigators
with a wide range of skills focused on revealing the mechanisms
of beta cell loss and potential regeneration in people with type
1 and 2 diabetes. He is director of the LHIRC islet isolation and
physiology core. He is the Editor in Chief of the journal Diabetes.
He is also the Chief of the Division of Endocrinology, Diabetes
and Hypertension. His clinical practice at UCLA focuses on care
of patients with diabetes. |
Peter Butler
Publications
1. Vore SJ, Aycock
ED, Veldhuis JD, Butler PC. Anesthesia suppresses insulin pulse mass
but increases orderliness of insulin concentration. Am. J. Physiol.
Endocrinol. Metab. 281: E93-E99, 2001.
Abstract
2. Kjems L, Kirby
BM, Welsh EM, Veldhuis JD, McIntyre SS, Yang DC, Lefèbvre P,
Butler PC. Decrease in b-cell mass leads to impaired pulsatile insulin
secretion, reduced post-prandial hepatic insulin clearance, and relative
hyperglucagonemia in the minipig. Diabetes 50: 2001-2012, 2001.
Abstract
3. Song SH, Kjems L, McIntyre SM, Johnson ML,
Veldhuis JD, Butler PC. Pulsatile insulin secretion by human pancreatic
islets. J.Clin.Endocrinol. Metab. 87(1):213-221, 2002.
Abstract
4. Juhl C, Grøfte T, Butler PC, Veldhuis
JD, Schmitz O, Pørksen N. Effects of fasting physiologically
pulsatile insulin release in healthy humans. Diabetes 51 (S1): S255-S257,
2002.
Abstract
5. Butler AE, Janson J, Bonner-Weir S, Ritzel
R, Rizza RA, Butler PC. b-cell deficit and increased apoptosis in humans
with type-2 diabetes. Diabetes 52 (1):102-110, 2003.
Abstract
6. Ritzel RA, Veldhuis JD, Butler PC. Glucose
stimulates pulsatile insulin secretion from human pancreatic islets
by increasing secretory burst mass; dose-response relationships. J.
Clin. Endocrinol. Metab. 88(2):742-747, 2003.
Abstract
7. Song SH, Rhodes CJ, Veldhuis JD, Butler
PC. Diazoxide attenuates glucose-induced defects in first phase insulin
release and pulsatile insulin secretion in human islets. Endocrinology.
144(8):3399-3405, 2003.
Abstract
8. Ritzel RA, Butler, PC. Replication increases
beta cell vulnerability to human islet amyloid polypeptide induced apoptosis.
Diabetes. 52:1701-1708, 2003.
Abstract
9. Butler AE, Janson J, Soeller WC, Butler
PC. Increased beta cell apoptosis prevents adaptive increase in beta
cell mass in mouse model of type-2 diabetes, evidence for role of islet
amyloid formation rather than direct action of amyloid. Diabetes. 52:2304-2314,
2003.
Abstract
10. Ritzel RA, Hansen JB, Veldhuis JD, Butler
PC. Induction of beta-cell rest by a KIR6.2/SUR1 selective KATP-channel
opener preserves beta-cell insulin stores and insulin secretion in human
islets cultured at high (11mM) glucose. J.Clin.Endocrinol Metab. 89:795-805,
2004.
Abstract
11. Janson J, Laedtke T, Parisi JE, O'Brien
P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer
disease. Diabetes. 53:474-481, 2004.
Abstract
12. Butler AE, Jang J, Gurlo T, Carty MD, Soeller
WS, Butler PC. Diabetes due to a progessive defect in beta cell mass
in rats transgenic for human islet amyloid polypeptide (HIP rat). A
new model for type-2 diabetes. Diabetes 53:1509-1516, 2004.
Abstract
13. Meier JJ, Veldhuis JD, Butler PC. Pulsatile
insulin secretion dictates systemic insulin delivery by regulating hepatic
insulin extraction in humans. Diabetes 54:1649-1656, 2005.
Abstract
14. Meier JJ, Bhushan A, Butler AE, Rizza RA,
Butler PC. Sustained beta-cell apoptosis in patients with long-standing
type 1 diabetes: Indirect evidence for islet regeneration? Diabetologia
48:2221-2228, 2005.
Abstract
15. Lin CY, Gurlo T, Haataja L, Hsueh WA, Butler
PC. Activation of peroxisome proliferator-activated receptors-g (PPAR-g)
by rosiglitazone protects human islet cells against human-islet amyloid
polypeptide toxicity by a PI3 kinase-dependent pathway. JCEM, 90:6678-6686,
2005.
Abstract
16. Meier JJ, Ritzel RA, Maedler K, Gurlo T,
Butler PC. Increased vulnerability of newly forming beta-cells to cytokine-induced
cell death. Diabetologia, 49:83-89, 2006.
Abstract
17. Meier JJ, Nauck MA, Butler PC. Comment
to: Patti ME, Mcmahon G, Mun EC et al. (2005) Severe hypoglycaemia post-gastric
bypass requiring partial pancreatectomy: evidence for inappropriate
insulin secretion and pancreatic islet hyperplasia. Diabetologia, 48:2236-2240,
2006.
Abstract
18. Ritzel RA, Butler AE, Rizza RA, Veldhuis
JD, Butler PC. Relationship between ß-cell mass and fasting blood
glucose concentration in humans. Diabetes Care, 29 (3):717-718, 2006.
Abstract
19. Meier JJ, Bhushan A, Butler PC. The potential
for stem cell therapy in diabetes. Pediatr Res, 59 (4):65R-73R, 2006.
Abstract
20. Meier JJ, Kjems LL, Veldhuis JD, Lefebvre
P, Butler PC. Post prandial suppression of glucagon secretion depends
on intact pulsatile insulin secretion: Further evidence for the intra-islet
insulin hypothesis. Diabetes, 55:1051-1056, 2006.
Abstract
21. Ritzel RA, Veldhuis JD, Butler PC. The
Mass but Not the Frequency, of Insulin Secretory Bursts in Isolated
Human Islets is Entrained by Oscillatory Glucose Exposure. Am J Physiol
Endocrinol Metab, 290:E750-E756, 2006.
Abstract
22. Matveyenko A, Butler PC. IAPP transgenic
rodents as models for Type 2 Diabetes. ILAR Journal, 47 (3):225-233,
2006.
Abstract
23. Meier JJ, Butler AE, Galasso R, Butler
PC. Hyperinsulinemic Hypoglycemia after Gastric Bypass Surgery is not
accompanied by Islet Hyperplasia or increased Beta-cell Turnover. Diabetes
Care, 29 (7):1554-1559, 2006.
Abstract
24. Meier JJ, Lin JC, Butler AE, Galasso R,
Martinez DS, Butler PC. Direct evidence of attempted beta-cell regeneration
in an 89-year old patient with recent onset Type 1 diabetes. Diabetologia,
49 (8):1838-1844, 2006.
Abstract
25. Matveyenko AV, Butler PC. b-cell Deficit
Due To Increased Apoptosis in the Human Islet Amyloid Polypeptide Transgenic
(HIP) Rat Recapitulates the Metabolic Defects Present In Type-2 Diabetes.
Diabetes, 55:2106-2114, 2006.
Abstract
26. Matveyenko AV, Veldhuis JD, Butler PC.
Mechanisms of impaired fasting glucose and glucose intolerance induced
by a ~50% pancreatectomy. Diabetes 55:2347-2356, 2006.
Abstract
27. Meier JJ, Hong-McAtee I, Galasso R, Veldhuis
JD, Moran A, Hering BJ, Butler PC. Intrahepatic Transplanted Islets
in Humans Secrete Insulin in a Coordinate Pulsatile Manner Directly
Into the Liver. Diabetes 55:2324-2332, 2006.
Abstract
28. Meier JJ, Nauk MA, Butler PC. Severe hypoglycemia
post-gastric bypass surgery requiring partial pancreatectomy: evidence
for inappropriate insulin secretion and pancreatic islet hyperplasia.
Diabeteologia, In Press, 2006.
Abstract: Pending
29. Meier JJ, Kayed R, Lin CY, Gurlo T, Haataja
L, Jayasinghe S, Langen R, Glabe CC, Butler PC. Inhibition of hIAPP
fibril formation does not prevent beta-cell death: Evidence for distinct
actions of oligomers and fibrils of hIAPP. Am J Physiol, In Press, 2006.
Abstract
30. Meier JJ, Butler AE, Galasso R, Rizza RA,
Butler PC. Increased islet beta cell replication adjacent to intrapancreatic
Gastrinomas in humans. Diabetologia, In Press 2006.
Abstract
31. Ritzel RA, Meier JJ, Lin CY, Veldhuis
JD, Butler PC. Human islet amyloid polypeptide oligomers disrupts cell
coupling, induces apoptosis, and impair insulin secretion in isolated
human islets. Diabetes (56):65-71, 2007.
Abstract
Reviews
32. Butler
AE, Butler PC. Life and death of ß-cells in the islet of Langerhans
in type 2 diabetes. International Diabetes Monitor, 18 (4), 2006.
Peer Reviewed Publications
1. Thompson CJ, Davies SN, Butler PC, Charlton JA, Baylis PH.
Osmoregulation of thirst and vasopressin secretion in insulin-dependent
diabetes mellitus.
Clin. Sci. 74: 599-606, 1988.
2. Møller N, Butler PC, Antsiferov MA, Alberti KGMM.
Effects of growth hormone on insulin sensitivity and forearm metabolism
in normal man. Diabetologia 32: 105-110, 1989.
3. Møller N, Beckwith R, Butler PC, Christensen NJ, Ørskov
H, Alberti KGMM.
Metabolic and hormonal responses to exogenous hyperthermia in man.
Clin. Endocrinol. 30: 651-660, 1989.
4. Bartlett K, Bhuiyan AKM J, Aynsley-Green A, Butler PC, Alberti KGMM.
Human forearm arteriovenous differences of carnitine, short-chain acylcarnitine
and long-chain acylcarnitine.
Clin. Sci. 77: 413-416, 1989.
5. Miller AR, Barr D, Marsh CL, Kryshak EJ, Butler PC, Rizza RA, Perkins
JD.
Diversion of the gastroduodenal vein: An in situ model of systemic insulin
drainage.
Diabetes Research and Clinical Practice 7: 109-114, 1989.
6. Butler PC, Kryshak EJ, Schwenk WF, Haymond MW, Rizza RA.
Hepatic and extrahepatic responses to insulin in NIDDM and nondiabetic
humans: Assessment in absence of artifact introduced by tritiated nonglucose
contaminants.
Diabetes 39: 217-225, 1990.
7. Kryshak EJ, Butler PC, Marsh C, Miller A, Barr D, Polonsky K, Perkins
JD, Rizza RA.
Pattern of postprandial carbohydrate metabolism and effects of portal
and peripheral insulin delivery.
Diabetes 39: 142-148, 1990.
8. Schwenk WF, Butler PC, Haymond MW, Rizza RA.
Underestimation of glucose turnover corrected with high-performance
liquid chromatography purification of [6 3H] glucose.
Am. J. Physiol. 258: E228-E233, 1990.
9. Goodship THJ, Butler PC, Rodham D, Clayton B, Home PD, Alberti KGMM.
Total body potassium in insulin-dependent diabetes mellitus.
Clin. Sci. 78: 377-381, 1990.
10. Barr D, Miller AR, Marsh CL, Kryshak EJ, Butler PC, Rizza RA, Perkins
JD.
Diversion of the gastroduodenal vein: A canine model for comparing portal
versus systemic insulin delivery.
Transplant Proc. 22: 702-703, 1990.
11. Conover CA, Butler PC, Wang M, Rizza RA, Lee PDK.
Lack of growth hormone effect on insulin-associated suppression of insulin-like
growth factor binding protein-1 in humans.
Diabetes 39: 1251-1256, 1990.
12. Butler PC, Kryshak EJ, Marsh M, Rizza RA.
Effect of insulin on oxidation of intracellularly and extracellularly
derived glucose in patients with NIDDM: Evidence for a primary defect
in glucose transport and/or phosphorylation but not glucose oxidation.
Diabetes 39: 1373-1380, 1990.
13. Butler PC, Chou J, Carter WB, Wang YN, Bu BH, Chang D, Chang JK,
Rizza RA.
Effects of meal ingestion on plasma amylin concentration in NIDDM and
nondiabetic humans.
Diabetes 39: 752-756, 1990.
14. Ebeling PR, Butler PC, Eastell R, Rizza RA, Riggs BL.
The nocturnal increase in growth hormone is not the cause of the nocturnal
increase in serum osteocalcin.
J. Clin. Endocrinol. Metab. 73: 368-372, 1991.
15. Butler PC, Rizza RA.
Contribution to postprandial hyperglycemia and effect on initial splanchnic
glucose clearance of hepatic glucose cycling in glucose-intolerant or
NIDDM patients.
Diabetes 40: 73-81, 1991.
16. Butler PC, Kryshak EJ, Rizza RA.
Mechanism of growth hormone-induced postprandial carbohydrate intolerance
in humans. Am. J. Physiol. 260: E513-E520, 1991.
17. Homan M, Nicholson CP, Katz H, Perkins J, Haymond MW, Miles J,
Jansen M, Butler PC, Rizza RA.
Effects of chronic insulin delivery on insulin action in dogs.
Diabetologia 34: 702-708, 1991.
18. Davis SN, Butler PC, Brown M, Beer S, Sobey W, Hanning I, Home
PD, Hales CN, Alberti KGMM.
The effects of human proinsulin on glucose turnover and intermediary
metabolism.
Metabolism 40: 953-961, 1991.
19. Katz H, Homan M, Butler PC, Rizza RA.
Use of [3-3H] glucose and [6-14C] glucose to measure glucose turnover
and glucose metabolism in humans.
Am. J. Physiol. 263: E17-E22, 1992.
20. Møller N, Schmitz O, Møller J, Butler PC.
Effects of a physiological growth hormone pulse on substrate metabolism
in insulin-dependent (Type I) diabetic subjects.
J. Clin. Endocrinol. Metab. 75: 432-436, 1992.
21. Usala A-L, Madigan T, Burguera B, Sinha MK, Caro JF, Cunningham
PR, Powell JG, and Butler PC.
Treatment of insulin-resistant diabetic ketoacidosis with insulin-like
growth factor I in an adolescent with insulin-dependent diabetes.
N. Engl. J. Med. 327: 853-857, 1992.
22. Butler PC, Caumo A, Zerman A, O'Brien PC, Cobelli C, Rizza RA.
Methods for assessment of the rate of onset and offset of insulin action
during nonsteady state in humans.
Am. J. Physiol. 264 Endocrinol. Metab. 27: E548-E560, 1993.
23. Katz H, Butler PC, Homan H, Zerman A. Caumo A, Cobelli C, Rizza
RA.
Hepatic and extrahepatic insulin action in humans: Measurement in the
absence of nonsteady-state error.
Am. J. Physiol. 264 Endocrinol. Metab. 27: E561-E566, 1993.
24. O'Brien TD, Butler AE, Roche PC, Johnson KH, Butler PC.
Islet amyloid polypeptide in human insulinomas: Evidence for intracellular
amyloidogenesis.
Diabetes 43: 329-336, 1994.
25. Pørksen N, Munn S, Ferguson D, O'Brien T, Veldhuis JD, Butler
PC.
Coordinate pulsatile insulin secretion by chronic intraportally transplanted
islets in the isolated perfused rat liver.
J. Clin. Invest. 94: 219-227, 1994.
26. Schmitz O, Pedersen SB, Mengel A, Pørksen N, Bak J, Møller
N, Richelsen B, Alberti KGMM, Butler PC, Ørskov H.
Augmented effect of short-term pulsatile versus continuous insulin delivery
on lipid metabolism but similar effect on whole-body glucose metabolism
in obese subjects.
Metabolism 43: 842-846, 1994.
27. O'Brien TD, Rizza RA, Carney JA, Butler PC.
Islet amyloidosis in a patient with chronic massive insulin resistance
due to antiinsulin receptor antibodies.
J. Clin. Endocrinol. Metab. 79: 290-292, 1994.
28. Rother KI, Carney JA, Couce M, Charlesworth J, Butler PC.
Islet amyloid polypeptide in pancreatic tissue of children with persistent
hyperinsulinemic hypoglycemia caused by primary islet hyperplasia and
nesidioblastosis.
J. Clin. Endocrinol. Metab. 80: 1956-1959, 1995.
29. Carter WB, Heath H, Rizza RA, Butler PC.
Measurement of plasma calcitonin gene-related peptide concentration
in healthy humans and patients with Type II diabetes mellitus: responses
to meal ingestion and hyperinsulinemia.
Endocrinology and Metabolism 2: 99-103, 1995.
30. O'Brien TD, Butler PC, Kreutter DK, Kane LA, Eberhardt NL.
Human islet amyloid polypeptide expression in COS-1 cells: a model of
intracellular amyloidogenesis.
Am. J. Pathol. 147: 609-616, 1995.
31. Pørksen N, Munn S, Steers J, Vore S, Veldhuis JD, Butler
PC.
Pulsatile insulin secretion accounts for 70% of total insulin secreted
during fasting.
Am. J. Physiol. 269 Endocrinol. Metab. 32: E478-E488, 1995.
32. Pørksen N, Munn S, Steers J, Veldhuis JD, Butler PC.
Impact of sampling technique on appraisal of pulsatile insulin secretion
by deconvolution and cluster analysis.
Am. J. Physiol. 269 Endocrinol. Metab. 32: E1106-E1114, 1995.
33. Couce M, O'Brien TD, Moran A, Roche PC, Butler PC.
Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis.
J. Clin. Endocrinol. Metab. 81: 1267-1272, 1996.
34. Gray RO, Butler PC, Beers TR, Kryshak EJ, Rizza RA.
Comparison of the ability of bread versus bread plus meat to treat and
prevent subsequent hypoglycemia in patients with insulin dependent diabetes
mellitus.
J. Clin. Endocrinol. Metab. 81: 1508-1511, 1996.
35. Vore SJ, Aycock ED, Butler PC.
Measurement of insulin pulsatility by sampling directly from the portal
vein: A surgical model for placement of long-term prehepatic vascular
sampling catheters.
Lab. Anim. Sci. 46: 202-205, 1996.
36. Pørksen N, Munn S, Steers J, Veldhuis JD, Butler PC.
Effects of somatostatin on pulsatile insulin secretion; selective inhibition
of insulin burst mass.
Am. J. Physiol. 270 Endocrinol.Metab.33: E1043-E1049, 1996.
37. Couce M, Kane LA, O'Brien TD, Charlesworth J, Soeller W, McNeish
J, Kreutter D, Roche P, Butler PC.
Treatment with growth hormone and dexamethasone in mice transgenic for
human islet amyloid polypeptide causes islet amyloidosis and b-cell
dysfunction.
Diabetes 45: 8 1094-1101, 1996.
38. Janson J, Soeller WC, Roche PC, Nelson RT, Torchia AJ, Kruetter
DK, Butler PC. Spontaneous diabetes mellitus in transgenic mice expressing
human islet amyloid polypeptide.
Proc. Natl. Acad. Sci. USA, 93: 7283-7288, 1996.
39. Pørksen N, Munn S, Steers J, Veldhuis JD, Butler PC.
Effects of glucose ingestion versus infusion on pulsatile insulin secretion:
the incretin effect is achieved by amplification of insulin secretory
burst mass.
Diabetes 45: 1317-1323, 1996.
40. Pørksen N, Munn S, Steers J, Schmitz O, Veldhuis JD, Butler
PC.
Mechanisms of Sulfonylurea's Stimulation of Insulin Secretion In Vivo:
selective amplification of insulin secretory burst mass.
Diabetes 45: 1792-1797, 1996.
41. O'Brien TD, Wagner JD, Litwak KN, Carlson CS, Cefalu WT, Jordan
KH, Johnson KH, Butler PC.
Islet amyloid and islet amyloid polypeptide in cynomolgus macaques (Macaca
fascicularis): an animal model of human non-insulin dependent diabetes
mellitus.
Vet. Pathol. 33: 479-485, 1996.
42. Schmitz O, Pørksen N, Nyholm B, Skjærbæk C,
Butler PC, Veldhuis JD, Pincus SM. Disorderly and Nonstationary Insulin
Secretion in Relatives of Patients with NIDDM. Am. J. Physiol. Endocrinol
Metab. 35: E218-E226, 1997.
43. Pørksen N, Hussain MA, Bianda TL, Nyholm B, Christianen
JS, Butler PC, Veldhuis JD, Froesch ER and Schmitz O.
IGF-I inhibits burst mass of pulsatile insulin secretion at supraphysiological
and low IGF-I infusion rates.
Am. J. Physiol. 272 Endocrinol Metab. 35: E352-E358, 1997.
44. Pørksen N, Nyholm B, Veldhuis JD, Butler PC, Schmitz O.
In humans at least seventy-five percent of overall insulin secretion
arises from punctuated high-frequency insulin secretory bursts.
Am. J. Physiol. Endocrinol Metab. 36: E908-914, 1997.
45. Kudva YC, Hiddinga HB, Butler PC, Mueske CS, Eberhardt NL.
Small heat shock proteins inhibit in vitro A 1-42 amyloidogenesis.
FEBS Letters 416: 117-121, 1997.
46. Pørksen N, Grøfte T, Nyholm B, Holst JJ, Pincus SM,
Veldhuis JD, Schmitz O, Butler PC.
Glucagon-like peptide 1 increases mass but not frequency or orderliness
of pulsatile insulin secretion.
Diabetes 47: 45-49, 1998
47. Soeller W, Janson J, Hart SE, Parker JC, Carty MD, Stevenson RW,
Kreutter DK, Butler PC.
Islet Amyloid-Associated Diabetes Mellitus in Obese Avy/a Mice Expressing
Human Islet Amyloid Polypeptide.
Diabetes 47: 743-750, 1998.
48. Kudva YG, Mueske C, Butler PC, Eberhardt NL.
A novel assay in vitro of human islet amyloid polypeptide amyloidogenesis
and effects of insulin secretory vesicle peptides on amyloid formation.
Biochemical Journal 331: 809-813, 1998.
49. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC.
The mechanism of islet amyloid polypeptide toxicity is membrane disruption
by intermediate-sized toxic amyloid particles.
Diabetes 48: 491-498, 1999.
50. Laedtke T, Kjems L, Pørksen N, Schmitz, O, Veldhuis JD,
Kao PC, Butler PC.
Overnight inhibition of insulin secretion restores pulsatility and the
proinsulin/insulin ratio in Type 2 diabetes.
Am. J. Physiol. Endocrinol. Metab. 279:E 520-528, 2000.
51. Song SH, McIntyre SM, Shah H, Veldhuis, JD, Hayes, PC, Butler PC.
Direct measurement of pulsatile insulin secretion from the portal vein
in human subjects. J. Clin. Endocrinol. Metab. 85: 4491-4499, 2000.
52. Nyholm B, Pørksen N, Juhl CB, Gravhold CH, Butler PC, Weeke
J, Veldhuis JD, Pincus S, Schmitz O. Assessment of insulin secretion
in relatives of patients with Type 2 (non-insulin-dependent, NIDDM)
diabetes mellitus: evidence of early -cell dysfunction.
Metabolism: Clinical & Experimental 49: (7): 896-905, 2000.
53. Vore SJ, Aycock ED, Veldhuis JD, Butler PC.
Anesthesia suppresses insulin pulse mass but increases orderliness of
insulin concentration.
Am. J. Physiol. Endocrinol. Metab. 281: E93-E99, 2001.
54. Kjems L, Kirby BM, Welsh EM, Veldhuis JD, McIntyre SS, Yang DC,
Lefèbvre P, Butler PC.
Decrease in -cell mass leads to impaired pulsatile insulin secretion,
reduced post-prandial hepatic insulin clearance, and relative hyperglucagonemia
in the minipig.
Diabetes 50: 2001-2012, 2001.
55. Song SH, Kjems L, McIntyre SM, Johnson ML, Veldhuis JD, Butler PC.
Pulsatile insulin secretion by human pancreatic islets.
J.Clin.Endocrinol. Metab. 87(1):213-221, 2002.
56. Pørksen N., Hollingdal M, Juhl C, Butler PC, Veldhuis JD,
Schmitz, O.
Pulsatile insulin secretion: detection, regulation, and role in diabetes.
Diabetes 51 (S1): S245-S254, 2002.
57. Juhl C, Grøfte T, Butler PC, Veldhuis JD, Schmitz O, Pørksen
N.
Effects of fasting physiologically pulsatile insulin release in healthy
humans.
Diabetes 51 (S1): S255-S257, 2002.
58. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler
PC.
-cell deficit and increased apoptosis in humans with type-2 diabetes.
Diabetes 52 (1):102-110, 2003.
59. Ritzel RA, Veldhuis JD, Butler PC.
Glucose stimulates pulsatile insulin secretion from human pancreatic
islets by increasing secretory burst mass; dose-response relationships.
J. Clin. Endocrinol. Metab. 88(2):742-747, 2003.
60. Song SH, Rhodes CJ, Veldhuis JD, Butler PC.
Diazoxide attenuates glucose-induced defects in first phase insulin
release and pulsatile insulin secretion in human islets.
Endocrinology. 144(8):3399-3405, 2003.
61. Ritzel RA, Butler, PC.
Replication increases beta cell vulnerability to human islet amyloid
polypeptide induced apoptosis.
Diabetes. 52:1701-1708, 2003.
62. Butler AE, Janson J, Soeller WC, Butler PC.
Increased beta cell apoptosis prevents adaptive increase in beta cell
mass in mouse model of type-2 diabetes, evidence for role of islet amyloid
formation rather than direct action of amyloid.
Diabetes. 52:2304-2314, 2003.
63. Ritzel RA, Hansen JB, Veldhuis JD, Butler PC.
Induction of beta-cell rest by a KIR6.2/SUR1 selective KATP-channel
opener preserves beta-cell insulin stores and insulin secretion in human
islets cultured at high (11mM) glucose.
J.Clin.Endocrinol Metab. 89:795-805, 2004.
64. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler
PC.
Increased risk of type 2 diabetes in Alzheimer disease.
Diabetes. 53:474-481, 2004.
65. Butler AE, Jang J, Gurlo T, Carty MD, Soeller WS, Butler PC.
Diabetes due to a progessive defect in beta cell mass in rats transgenic
for human islet amyloid polypeptide (HIP rat). A new model for type-2
diabetes.
Diabetes 53:1509-1516, 2004.
66. Meier JJ, Veldhuis JD, Butler PC.
Pulsatile insulin secretion dictates systemic insulin delivery by regulating
hepatic insulin extraction in humans.
Diabetes 54:1649-1656, 2005.
67. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC.
Sustained beta-cell apoptosis in patients with long-standing type 1
diabetes: Indirect evidence for islet regeneration?
Diabetologia 48:2221-2228, 2005.
68. Lin CY, Gurlo T, Haataja L, Hsueh WA, Butler PC.
Activation of peroxisome proliferator-activated receptors- (PPAR- )
by rosiglitazone protects human islet cells against human-islet amyloid
polypeptide toxicity by a PI3 kinase-dependent pathway.
JCEM, 90:6678-6686, 2005.
69. Meier JJ, Ritzel RA, Maedler K, Gurlo T, Butler PC.
Increased vulnerability of newly forming beta-cells to cytokine-induced
cell death.
Diabetologia, 49:83-89, 2006.
70. Meier JJ, Nauck MA, Butler PC.
Comment to: Patti ME, Mcmahon G, Mun EC et al. (2005) Severe hypoglycaemia
post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate
insulin secretion and pancreatic islet hyperplasia.
Diabetologia, 48:2236-2240, 2006.
71. Ritzel RA, Butler AE, Rizza RA, Veldhuis JD, Butler PC.
Relationship between ß-cell mass and fasting blood glucose concentration
in humans.
Diabetes Care, 29 (3):717-718, 2006.
72. Meier JJ, Bhushan A, Butler PC.
The potential for stem cell therapy in diabetes.
Pediatr Res, 59 (4):65R-73R, 2006.
73. Meier JJ, Kjems LL, Veldhuis JD, Lefebvre P, Butler PC.
Post prandial suppression of glucagon secretion depends on intact pulsatile
insulin secretion: Further evidence for the intra-islet insulin hypothesis.
Diabetes, 55:1051-1056, 2006.
74. Ritzel RA, Veldhuis JD, Butler PC.
The Mass but Not the Frequency, of Insulin Secretory Bursts in Isolated
Human Islets is Entrained by Oscillatory Glucose Exposure.
Am J Physiol Endocrinol Metab, 290:E750-E756, 2006.
75. Butler AE, Butler PC.
Life and death of ß-cells in the islet of Langerhans in type 2
diabetes.
International Diabetes Monitor, 18 (4), 2006.
76. Matveyenko A, Butler PC.
IAPP transgenic rodents as models for Type 2 Diabetes.
ILAR Journal, 47 (3):225-233, 2006.
77. Meier JJ, Butler AE, Galasso R, Butler PC.
Hyperinsulinemic Hypoglycemia after Gastric Bypass Surgery is not accompanied
by Islet Hyperplasia or increased Beta-cell Turnover.
Diabetes Care, 29 (7):1554-1559, 2006.
78. Meier JJ, Lin JC, Butler AE, Galasso R, Martinez DS, Butler PC.
Direct evidence of attempted beta-cell regeneration in an 89-year old
patient with recent onset Type 1 diabetes.
Diabetologia, 49 (8):1838-1844, 2006.
79. Matveyenko AV, Butler PC.
-cell Deficit Due To Increased Apoptosis in the Human Islet Amyloid
Polypeptide Transgenic (HIP) Rat Recapitulates the Metabolic Defects
Present In Type-2 Diabetes.
Diabetes, 55:2106-2114, 2006.
80. Matveyenko AV, Veldhuis JD, Butler PC.
Mechanisms of impaired fasting glucose and glucose intolerance induced
by a ~50% pancreatectomy.
Diabetes 55:2347-2356, 2006.
81. Meier JJ, Hong-McAtee I, Galasso R, Veldhuis JD, Moran A, Hering
BJ, Butler PC.
Intrahepatic Transplanted Islets in Humans Secrete Insulin in a Coordinate
Pulsatile Manner Directly Into the Liver.
Diabetes 55:2324-2332, 2006.
82. Meier JJ, Kayed R, Lin CY, Gurlo T, Haataja L, Jayasinghe S, Langen
R, Glabe CG, Butler PC.
Inhibition of human IAPP fibril formation does not prevent beta-cell
death: Evidence for distinct actions of oligomers and fibrils of human
IAPP.
Am J Physiol Endocrinol Metab 291: E1317-24, 2006.
83. Meier JJ, Butler AE, Galasso R, Rizza RA, Butler PC.
Increased islet beta cell replication adjacent to intrapancreatic Gastrinomas
in humans.
Diabetologia 49(11):2689-96, 2006.
84. Ritzel RA, Meier JJ, Lin CY, Veldhuis JD, Butler PC.
Human islet amyloid polypeptide oligomers disrupts cell coupling, induces
apoptosis, and impair insulin secretion in isolated human islets.
Diabetes 56(1):65-71, 2007.
85. Cobelli C, Toffolo GM, Man CD, Campioni M, Denti P, Caumo A, Butler
P, Rizza R. Assessment of beta-cell function in humans, simultaneously
with insulin sensitivity and hepatic extraction, from intravenous and
oral glucose tests. Am J Physiol Endocrinol Metab. 293:E1-E15, 2007
86. Lin CY, Gurlo T, Kayed R, Butler AE, Haataja L, Glabe CG, Butler
PC.
Toxic Human Islet Amyloid Polypeptide (h-IAPP) Oligomers are Intracellular,
and Vaccination to Induce Anti-Toxic Oligomer Antibodies Does not Prevent
h-IAPP Induced ß-Cell Apoptosis in h-IAPP Transgenic Mice.
Diabetes 56(5):1324-32, 2007.
87. Butler AE, Huang CJ, Rao N, Bhushan A, Hogan WJ, Rizza RA, Butler
PC.
Hematopoietic stem cells derived from adult donors are not a source
of pancreatic beta cells in adult non diabetic humans.
Diabetes 56(7):1810-1816, 2007.
88. Huang CJ, Lin CY, Haataja L, Gurlo T, Butler AE, Rizza RA, Butler
PC.
High expression rates of human islet amyloid polypeptide induce endoplasmic
reticulum stress-mediated beta cell apoptosis, a characteristic of humans
with Type 2 but not Type 2 Diabetes.
Diabetes, 56(8):2016-27, 2007.
89. Butler AE, Galasso R, Meier JJ, Basu R, Rizza RA, Butler PC.
Modestly increased beta cell apoptosis but no increased beta cell replication
in recent-onset type 1 diabetic patients who died of diabetic ketoacidosis.
Diabetologia. 50(11):2323-31, 2007.
90. Saisho Y, Butler AE, Meier JJ, Monchamp T, Allen-Auerbach M, Rizza
RA, Butler PC.
Pancreas volumes in humans from birth to age one hundred taking into
account sex, obesity, and presence of type-2 diabetes.
Clin Anat. 20(8):933-42, 2007.
91. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol
L, Wu J, Breydo L, Thompson JL, Rasool S, Gurlo T, Butler P, Glabe CG.
Fibril specific, conformation dependent antibodies recognize a generic
epitope common to amyloid fibrils and fibrillar oligomers that is absent
in prefibrillar oligomers.
Mol Neurodegener. 2(1):18, 2007.
92. Huang CJ, Haataja L, Galasso R, Gurlo T, Butler AE, Wu X, Soeller
W, Butler PC.
Induction of endoplasmic reticulum stress induced beta cell apoptosis
and accumulation of polyubiquinated proteins by human islet amyloid
polypeptide.
Am J Physiol Endocrinol Metab. 293(6):E1656-62, 2007.
93. Butler PC, Meier JJ, Bhushan A.
The replication of beta cells in normal physiology, in disease and for
therapy.
Nat Clin Pract Endocrinol Metab. 3(11):758-68, 2007.
94. Haataja L, Gurlo T, Huang CJ, Butler PC.
Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis.
Endocrine Reviews. 29(3):303-16, 2008.
95. Meier JJ, Butler AE, Saisho Y, Monchamp T, Galasso R, Bhushan A,
Rizza RA, Butler PC.
Beta-cell replication is the primary mechanism subserving the postnatal
expansion of beta-cell mass in humans.
Diabetes. 57(6):1584-94, 2008.
96. Saisho Y, Butler AE, Butler PC.
Pancreatic fat content and beta-cell function in men with and without
type 2 diabetes: response to Tushuizen et al.
Diabetes Care. 31(5):e38; author reply e39, 2008.
97. Matveyenko AV, Veldhuis JD, Butler PC.
Measurement of pulsatile insulin secretion in the rat, direct sampling
from the hepatic portal vein.
Am J Physiol Endocrinol Metab 2008 Jun 24 [Epub ahead of print].
|
